Cubist Systematic Strategies, LLC Protalix Bio Therapeutics, Inc. Transaction History
Cubist Systematic Strategies, LLC
- $15.6 Billion
- Q1 2025
A detailed history of Cubist Systematic Strategies, LLC transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 53,380 shares of PLX stock, worth $74,732. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,380
Previous 29,307
82.14%
Holding current value
$74,732
Previous $56,000
142.86%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding PLX
# of Institutions
70Shares Held
8.27MCall Options Held
227KPut Options Held
54.5K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.19MShares$1.66 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny963KShares$1.35 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA859KShares$1.2 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL685KShares$958,6610.0% of portfolio
-
Marshall Wace, LLP London, X0615KShares$861,1190.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $69.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...